Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
S.C. Smith Jr, S.N. Blair, R.O. Bonow, L.M. Brass, M.D. Cerqueira, K. Dracup, et al.
AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology.
J Am Coll Cardiol, 38 (2001), pp. 1581-1583
[2.]
Scandinavian Simvastatin Survival Study Group.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
Lancet, 344 (1994), pp. 1383-1389
[3.]
Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
N Engl J Med, 339 (1998), pp. 1349-1357
[4.]
F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, T.G. Cole, et al.
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
N Engl J Med, 335 (1996), pp. 1001-1009
[5.]
The Lipid Research Clinics Coronary Primary Prevention Trial results.
The relationship of reduction in incidence of coronary heart disease to cholesterol lowering.
JAMA, 251 (1984), pp. 365-374
[6.]
The Lipid Research Clinics Investigators.
The Lipid Research Clinics Coronary Primary Prevention Trial. Results of 6 years of posttrial follow-up.
Arch Intern Med, 152 (1992), pp. 1399-1410
[7.]
G.G. Schwartz, A.G. Olsson, M.D. Ezekowitz, P. Ganz, M.F. Oliver, D. Waters, et al.
Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
JAMA, 285 (2001), pp. 1711-1718
[8.]
P.R. Hebert, J.M. Gaziano, K.S. Chan, C.H. Hennekens.
Cholesterol lowering with statin drugs, risk of stroke, and total mortality.
JAMA, 278 (1997), pp. 313-321
[9.]
CAPRIE Steering Committee.
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).
Lancet, 348 (1996), pp. 1329-1339
[10.]
C.M. Viscoli, R.I. Horwitz, B.H. Singer.
Beta-blockers after myocardial infarction: influence of first-year clinical course on long-term effectiveness.
Ann Intern Med, 118 (1993), pp. 99-105
[11.]
Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction.
N Engl J Med, 304 (1981), pp. 801-807
[12.]
N. Freemantle, J. Cleland, P. Young, J. Mason, J. Harrison.
Beta Blockade after myocardial infarction: systematic review and meta regression analysis.
BMJ, 26 (1999), pp. 1730-1737
Copyright © 2002. Elsevier España, S.L. y Sociedad Española de Medicina Rural y Generalista (SEMERGEN)
